Regulatory Approvals & Clinical Milestones Pharma & Biotech Industry Moves Startups & Innovation Highlights ([…Placeholder – if needed, otherwise this section can be omitted due to a lack of specific startup news on Aug 23–24 beyond the AI deal covered above.]) (The content above demonstrates how startup news might be presented. If no significant startup…
Read more
Biobeat’s cuffless vital-sign patch received FDA clearance and CE marking for hospital-grade remote monitoring, enabling cuffless measurement of blood pressure, heart rate, SpO2, and respiratory rate via PPG and AI. On June 19, PharmaSens and SiBionics announced niia™ signature, an all-in-one patch that combines a continuous glucose monitor with an insulin pump, unveiled at ADA…
Read more
Late 2024, the first FDA-approved CRISPR-based therapy exagamglogene autotemcel (Casgevy) reached patients, with Vertex reporting $2 million in revenue from this sickle-cell gene-editing therapy in Q3 2024. Prime Medicine’s PM359 autologous CRISPR prime-edited cell therapy for chronic granulomatous disease began a Phase I/II study in 2024, with initial first-in-human data expected in late 2025. Wave…
Read more
